Column Group III Gp, LP sold $2.4M of TNYA
owner at Tenaya Therapeutics, Inc.. 4,170,266 shares at an average of $0.57, traded Feb 24, 2026, filed Feb 26, 2026.
Score components
- +12Role10% owner
- +25Trade size$2.4M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +9.2%, 3m +31.2%, 6m +14.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-076814, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | SOpen-market sale Common Stockindirect: See Footnote | -309,228 | $0.62 | $190k | 1,649,281 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stockindirect: See Footnote | -349,212 | $0.62 | $215k | 1,862,545 | Feb 26, 2026 |
| Feb 25, 2026 | SOpen-market sale Common Stockindirect: See Footnote | -1,649,281 | $0.56 | $928k | 0 | Feb 26, 2026 |
| Feb 25, 2026 | SOpen-market sale Common Stockindirect: See Footnote | -1,862,545 | $0.56 | $1.0M | 0 | Feb 26, 2026 |
Related signals
Other insiders at Tenaya Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | Tenaya Therapeutics, Inc. | Faraz Ali Chief Executive Officer | $16k 22,232 shares | -5% | |
| 23Weak | Tenaya Therapeutics, Inc. | Whittemore Tingley Chief Medical Officer | $5,270 7,424 shares | -3% | |
| 40Moderate | Tenaya Therapeutics, Inc. | Faraz Ali Chief Executive Officer | $2,690 3,390 shares | -1% | |
| 30Weak | Tenaya Therapeutics, Inc. | Tomohiro Higa SVP, Finance | $1,178 1,485 shares | -1% | |
| 30Weak | Tenaya Therapeutics, Inc. | Whittemore Tingley Chief Medical Officer | $2,477 3,121 shares | -1% | |
| 55Moderate | Tenaya Therapeutics, Inc. | Column Group III Gp, LP owner | $505k 829,734 shares | -35% | |
| 40Moderate | Tenaya Therapeutics, Inc. | Faraz Ali Chief Executive Officer | $9,557 14,862 shares | -3% | |
| 30Weak | Tenaya Therapeutics, Inc. | Tomohiro Higa SVP, Finance | $2,231 3,469 shares | -3% | |
| 30Weak | Tenaya Therapeutics, Inc. | Whittemore Tingley Chief Medical Officer | $3,319 5,160 shares | -2% | |
| 82Strong | Tenaya Therapeutics, Inc. | Column Group III Gp, LP owner | $3.0M 4,400,290 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.